酪氨酸激酶(TK)系调控蛋白质磷酸化和去磷酸化的一组蛋白激酶,是细胞信号传导的主要成分。根据结构及功能的不同分为受体型TK和非受体型TK两大类。TK中发生突变者绝大多数是Ⅲ型受体TK超家族成员,其中最常见的受体型TK突变是FLT3、c-kit突变。激活或功能性突变的TK与急性白血病的发生发展有关。因此以TK为靶点,合成特异性TK抑制剂对AL进行靶向治疗具有一定的发展前景。本文对此研究进展进行综述。 Tyrosine kinases (TK) are a group of protein kinases that regulate the phosphorylation and dephosphorylation of proteins and are the major components of cellular signaling. According to the different structure and function is divided into receptor TK and non-receptor TK two categories. Most of the mutations that occur in TK are members of the TK superfamily of type III receptors, the most common of which is the variant of the FLT3, c-kit. TK activation or functional mutations associated with the occurrence and development of acute leukemia. Therefore, TK as a target, the synthesis of specific inhibitors of the TK targeted therapy of AL has some prospects for development. This article reviews the progress of this study.